Intervention not reported
Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · liver transplant recipients
1 finding from 1 review
SAEs · people with dementia
Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with moderate NMB (very low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with shallow NMB (very low certainty).
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures
1 finding from 1 review
Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes serious adverse events (SAEs) start of surgery until 8 hours after… compared with moderate NMB (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review